CME Group Inc: Earning High Marks from Investment Gurus

CME Group Inc impresses with a strong rating of 75% from Validea's Multi-Factor Investor model. This rating highlights the company's solid fundamentals and stock valuation, suggesting potential upward movement in stock prices. Investors may take interest in CME as it meets several quality criteria.

Date: 28-02-2025

AI Rating: 6

Overview of CME Group Inc's Performance

CME Group Inc has received a 75% rating based on the Multi-Factor Investor model, indicating that the company is perceived favorably based on its underlying fundamentals and stock valuation. This rating is significant as it reflects strong interest from the model's investment criteria.

Market Capitalization

CME has received a "PASS" on market capitalization. This means that the company's size, which often correlates with stability and low volatility, positions it well for investors seeking growth in a lower-risk environment.

Standard Deviation

Also rated as a "PASS", CME's stock produces less price fluctuation compared to its peers. This characteristic makes it attractive to conservative investors who are wary of high volatility typically associated with growth stocks.

Twelve Minus One Momentum and Net Payout Yield

Both of these areas received a "NEUTRAL" rating. This neutrality suggests that while CME is not currently exhibiting strong momentum, it also is not showing weakness. This balanced performance can reassure investors that significant downturns are unlikely in the near term.

Final Rank

Interestingly, the final assessment for CME is rated as a "FAIL". This is a critical point that investors should note. Despite the favorable aspects highlighted earlier, this rating might indicate issues that could hinder investment interest significantly.

In summary, CME Group Inc shows robust ratings in several categories, attracting potential investor interest. However, the "FAIL" rating in the final rank suggests caution, as there may be underlying issues that need addressing for long-term stability and growth.

Stocks: CME